Werbung
Werbung

BBOT

BBOT logo

BridgeBio Oncology Therapeutics, Inc. Common Stock

13.28
USD
Gesponsert
-0.02
-0.17%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

13.09

-0.19
-1.45%

BBOT Ergebnisberichte

Positives Überraschungsverhältnis

BBOT übertreffen die 0 der letzten 1Schätzungen.

%

Nächster Bericht

Datum des nächsten Berichts
03. März 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.54
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
-47.57%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
--

BridgeBio Oncology Therapeutics, Inc. Common Stock earnings per share and revenue

On 12. Nov. 2025, BBOT reported earnings of -1.03 USD per share (EPS) for Q3 25, missing the estimate of -0.39 USD, resulting in a -159.05% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.98% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.54 USD, with revenue projected to reach -- USD, implying an decrease of -47.57% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, BridgeBio Oncology Therapeutics, Inc. Common Stock reported EPS of -$1.03, missing estimates by -159.05%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.98%, changed from $12.63 before the earnings release to $12.38 the day after.
The next earning report is scheduled for 03. März 2026.
Based on 9 analysts, BridgeBio Oncology Therapeutics, Inc. Common Stock is expected to report EPS of -$0.54 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung